



06-18-07

Express Mail: EV654847303US

Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis
Serial No.: 10/531,552
Filed: April 13, 2005
For: METHODS OF USING AND
COMPOSITIONS COMPRISING
SELECTIVE CYTOKINE
INHIBITORY DRUGS FOR THE
TREATMENT AND MANAGEMENT
OF MYELODYSPLASTIC
SYNDROMES

Confirmation No.: 3548
Art Unit: 1617
Examiner: Wang, Shengjun
Attorney Dkt No.: 9516-075-999
(CAM: 501872-999074)

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references A1-A104, B1-B11 and C1-C107 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed reference is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application. Should any fee be required, please charge such fee to Jones Day Deposit Account No. 50-3013.

Date: June 15, 2007

Respectfully submitted,



Yean-Sil Moon (Reg. No.) 52,042
For: Anthony M. Insogna 35,203
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

ATTY DOCKET NO.

9516-075-999

APPLICATION NO

10/531,552

APPLICANT

Zeldis

FILING DATE

April 13, 2005

GROUP

1617

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2001/0056114	12/27/01	D'Amato			
	A02	2002/0035090	3/21/02	Zeldis et al.			
	A03	2002/0052398	5/2/02	D'Amato			
	A04	2002/0054899	5/9/02	Zeldis			
	A05	2002/0061923	5/23/02	D'Amato			
	A06	2002/0161023	10/31/02	D'Amato			
	A07	2002/0173658	11/21/02	Muller et al.			
	A08	2002/0183360	12/5/02	Muller et al.			
	A09	2003/0028028	2/6/03	Man et al.			
	A10	2003/0045726	3/6/03	Muller			
	A11	2003/0069428	4/10/03	Muller et al.			
	A12	2003/0139451	7/24/03	Shah et al.			
	A13	2003/0144325	7/31/03	Muller et al.			
	A14	2003/0181428	9/25/03	Green et al.			
	A15	2003/0187024	10/2/03	D'Amato			
	A16	2003/0187052	10/2/03	Muller et al.			
	A17	2003/0191098	10/9/03	D'Amato			
	A18	2003/0235909	12/25/03	Hariri et al.			
	A19	2004/0019106	1/29/04	Muller et al.			
	A20	2004/0029832	2/12/04	Zeldis			
	A21	2004/0006096	1/8/04	Muller et al.			
	A22	2004/0077685	4/22/04	Figg et al.			
	A23	2004/0077686	4/22/04	Dannenberg et al.			
	A24	2004/0087546	5/6/04	Zeldis			
	A25	2004/0091455	5/13/04	Zeldis			
	A26	2004/0122052	6/24/04	Muller et al.			
	A27	2004/0147588	7/29/04	Man et al.			
	A28	2004/0167199	8/26/04	Muller et al.			
	A29	2004/0167174	8/26/04	Man et al.			
	A30	2004/0259873	12/23/04	Man et al.			
	A31	2005/0014727	1/20/05	Muller et al.			
	A32	2003/0114516	6/19/03	Muller et al.			
	A33	2006/0084815	4/20/06	Muller et al.			
	A34	2006/0025457	2/2/06	Muller et al.			
	A35	6,844,359	1/18/05	Muller			
	A36	6,699,899	3/2/04	Man et al.			

	A37	6,673,828	1/6/04	Green et al.			
	A38	6,667,316	12/23/04	Man et al.			
	A39	6,656,964	12/2/03	Muller et al.			
	A40	6,518,298	2/11/03	Green et al.			
	A41	6,518,281	2/11/03	Muller et al.			
	A42	6,479,554	11/12/02	Muller et al.			
	A43	6,469,045	10/22/02	D'Amato			
	A44	6,429,221	8/6/02	Muller et al.			
	A45	6,420,414	7/16/02	D'Amato			
	A46	6,326,388	12/4/01	Man et al.			
	A47	6,284,780	9/4/01	Muller et al.			
	A48	6,262,101	7/17/01	Muller et al.			
	A49	6,228,879	5/8/01	Green et al.			
	A50	6,225,348	5/1/01	Paulson			
	A51	6,218,369	4/17/01	Bombardelli et al.			
	A52	6,214,857	4/10/01	Muller et al.			
	A53	6,200,987	3/13/01	Muller			
	A54	6,180,644	1/30/01	Muller et al.			
	A55	6,130,226	10/10/00	Muller et al.			
	A56	6,075,041	6/13/00	Muller			
	A57	6,046,221	4/4/00	Muller et al.			
	A58	6,020,358	1/4/00	Muller et al.			
	A59	6,015,803	1/18/00	Wirotko			
	A60	6,011,050	1/4/00	Muller et al.			
	A61	6,001,368	12/14/99	Jenks			
	A62	5,968,945	10/19/99	Muller et al.			
	A63	5,929,117	7/27/99	Muller et al.			
	A64	5,877,200	3/2/99	Muller			
	A65	5,801,195	9/1/98	Muller et al.			
	A66	5,770,589	6/23/98	Billson			
	A67	5,736,570	4/7/98	Muller			
	A68	5,733,566	3/31/98	Lewis			
	A69	5,728,845	3/17/98	Muller			
	A70	5,728,844	3/17/98	Muller			
	A71	5,712,291	1/27/98	D'Amato			
	A72	5,703,098	12/30/97	Muller			
	A73	5,698,579	12/16/97	Muller			
	A74	5,674,533	10/7/97	Santus et al.			
	A75	5,658,940	8/19/97	Muller et al.			
	A76	5,643,915	7/1/97	Andrulis et al.			
	A77	5,639,476	6/17/97	Oshlack et al.			
	A78	5,632,984	5/27/97	Wong et al.			
	A79	5,605,914	2/25/97	Muller			
	A80	5,591,767	1/7/97	Mohr et al.			
	A81	5,580,755	12/3/96	Souza			

	A82	5,528,823	6/25/96	Rudy et al.			
	A83	5,463,063	10/31/95	Muller			
	A84	5,393,870	2/28/95	Deeley et al.			
	A85	5,391,485	2/21/95	Deeley et al.			
	A86	5,385,901	1/31/95	Kaplan et al.			
	A87	5,354,556	10/11/94	Sparks et al.			
	A88	5,288,487	2/22/94	Kawashima et al.			
	A89	5,229,496	7/20/93	Deeley et al.			
	A90	5,134,127	7/28/92	Stella et al.			
	A91	5,120,548	6/9/92	McClelland et al.			
	A92	5,073,543	12/17/91	Marshall et al.			
	A93	5,059,595	10/22/91	LeGrazie			
	A94	4,999,291	3/12/91	Souza			
	A95	4,810,643	3/7/89	Souza			
	A96	4,008,719	2/22/77	Theeuwes et al.			
	A97	3,916,899	11/4/75	Theeuwes et al.			
	A98	3,845,770	11/5/74	Theeuwes et al.			
	A99	3,598,123	8/10/71	Zaffaroni			
	A100	3,536,809	10/27/70	Applezweig			
	A101	7,173,058	2/6/07	Muller et al.			
	A102	6,962,940	11/8/05	Muller et al.			
	A103	6,911,464	6/28/05	Man et al.			
	A104	7,034,052	4/25/06	Muller et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 03/080049	10/2/03	PCT				
	B02	WO 03/080048	10/2/03	PCT				
	B03	WO 01/87307	11/22/01	PCT				
	B04	WO 01/87306	11/22/01	PCT				
	B05	WO 01/45702	6/28/01	PCT				
	B06	WO 01/34606	5/17/01	PCT				
	B07	WO 99/06041	2/11/99	PCT				
	B08	WO 97/23457	7/3/97	PCT				
	B09	WO 97/08143	3/6/97	PCT				
	B10	WO 95/01348	1/12/95	PCT				
	B11	JP 11-286455	10/19/99	Japan				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C01	Beazley et al., 1985, "Malignant stricture at the confluence of the biliary tree: diagnosis and management," <i>Surg. Annu.</i> 17:125-41
	C02	Bellamy et al., 2001, "Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes," <i>Blood</i> 97:1427-1434
	C03	Bennett et al., 1985, "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group," <i>Ann. Intern. Med.</i> 103(4):620-625
	C04	Bennett et al., 1982, "Proposals for the classification of the myelodysplastic syndromes," <i>Br. J. Haematol.</i> 51:189-199

C05	Besa, 1992, "Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues," <i>Med. Clin. North Am.</i> 76(3):599-617
C06	Besa et al., 1990, "Erythroid response of severely anemic or transfusion-dependent patients with myelodysplastic syndrome to recombinant human erythropoietin (EPO) does not correlate with baseline serum EPO levels," <i>Blood</i> 76(10 Supp. 1):133a Abstract 521
C07	Bowen et al., 1991, "The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin," <i>Br. J. Haematol.</i> 77(3):419-423
C08	Bumm et al., 2003, "Emergences of clonal cytogenetic abnormalities in pH- cells in some CML patients in cytogenic remission to imatinib but restoration of polyclonal hematopoiesis in the majority," <i>Blood</i> 101:1941-1949
C09	Cancer Therapy Evaluation Program, 1998, "Common toxicity criteria," Version 2.0, Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Institutes of Health, March, 1998. (Accessed June 13, 2007, at http://ctep.cancer.gov/reporting/ctc.html .)
C10	Cartensen, 1995, <i>Drug Stability: Principles & Practice</i> , 2nd ed., Marcel Dekker, New York, NY pp. 379-380
C11	Cheson et al., 2000, "Report of an international working group to standardize response criteria for myelodysplastic syndromes," <i>Blood</i> 96:3671-3674
C12	Claessens et al., 2002, "In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis," <i>Blood</i> 99:1594-1601
C13	Corral et al., 1999, "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha," <i>J. Immunol.</i> 163:380-386
C14	Corral et al., 1999, <i>Ann. Rheum. Dis.</i> 58(Supp. I):1107-1113
C15	Costa et al., 1998, <i>Blood</i> 92(10:suppl. 1):235b, Abstract #4007
C16	D'Amato et al., 1994, "Thalidoide is an inhibitor of angiogenesis," <i>PNAS USA</i> 91(9):4082-4085
C17	Davies et al., 2001, "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma," <i>Blood</i> 98:210-216
C18	Deeg et al., 2002, "Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study," <i>Leukemia</i> 16:162-164
C19	Dexter, 1989, "Haemopoietic growth factors," <i>Br. Med. Bull.</i> 45(2):337-349
C20	Dexter, 1987, "Growth factors involved in haemopoiesis," <i>J. Cell. Sci.</i> 88 (Pt 1):1-6
C21	Dredge et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," <i>Br. J. Cancer</i> 87(10):1166-1172
C22	Ehrenpreis et al., 1999, "Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial," <i>Gastroenterology</i> 117(6):1271-1277
C23	Emens et al., 2001, "Chemotherapy: friend or foe to cancer vaccines?" <i>Curr. Opin. Mol. Ther.</i> 3(1):77-84
C24	Gersuk et al., 1996, "Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome," <i>Blood</i> 88(3):1122-1123
C25	Goldberg et al., 2003, "Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy," <i>Blood</i> 101:781
C26	Goldberg et al., 1990, "Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease," <i>Cancer Res.</i> 50(21):6876-6881
C27	Greenberg et al., 1997, "International scoring system for evaluating prognosis in myelodysplastic syndromes," <i>Blood</i> 89(6):2079-2088
C28	Gupta et al., 2001, "Adherences of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," <i>Leukemia</i> 15:1950-1961
C29	Handman et al., 1979, "Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages," <i>J. Immunol.</i> 122(3):1134-1137
C30	Harris et al., 1999, "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997," <i>J. Clin. Oncol.</i> 17(12):3835-3849
C31	Hellstrom-Lindberg et al., 1997, "Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model," <i>Br. J. Haematol.</i> 99:344-351
C32	Hellstrom et al., 1990, "Treatment of myelodysplastic syndromes with recombinant human erythropoietin," <i>Blood</i> 76(Supp. 1):279a Abstract 1106
C33	Jaffe et al., eds., 2001, "World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues," Lyon, France: IARC Press pp. 61-74
C34	Kaplan et al., 1958, "Nonparametric estimation from incomplete observations," <i>J. Am. Stat. Assoc.</i> 53:457-481
C35	Kitagawa et al., 1997, "Overexpression of tumor necrosis factor (TNF)- α and interferon (INF)- γ by bone marrow cells from patients with myelodysplastic syndromes," <i>Leukemia</i> 11:2049-2054
C36	Koch, 1985, "Thalidomide and congeners as anti-inflammatory agents," <i>Prog. Med. Chem.</i> 22:165-242
C37	Kropff, 2000, <i>Blood</i> 96(11 part 1):168a, Abstract #725

C38	Kurland et al., 1979, "Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation," <i>Proc. Natl. Acad. Sci. USA</i> 76(5):2326-2330
C39	Lentzsch et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," <i>Leukemia</i> 17(1):41-44
C40	List et al., 2005, "Efficacy of Lenalidomide in myelodysplastic syndromes," <i>N. Engl. J. Med.</i> 352(6):549-557
C41	List et al., 2004, "Myelodysplastic syndromes," Wintrobe's Clinical Hematology, 11 th ed., Philadelphia: Lippincott Williams & Wilkins pp. 2207-2234
C42	List et al., 2004, "Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositol 3-kinase-dependent clonogenic response in acute myeloid leukemia cells," <i>Exp. Hematol.</i> 32:526-535
C43	List, 2002, "The immunomodulatory thalidomide, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced p13 kinase/akt activation," <i>Blood</i> 100(11):139a, Abstract #521
C44	Maciejewski et al., 2002, "A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome," <i>Br. J. Haematol.</i> 117:119
C45	McCann, 1999, <i>Drug Topics</i> pp. 41-42 (June 21, 1999)
C46	<i>The Merck Manual</i> , 1999, 17 th ed., pp. 953-955
C47	Metcalf, 1985, "The granulocyte-macrophage colony-stimulating factors," <i>Science</i> 229(4708):16-22
C48	Moller et al., 1997, "Inhibition of IL-12 production by thalidomide," <i>J. Immunol.</i> 159(10):5157-5161
C49	Moore, 1991, "The clinical use of colony stimulating factors," <i>Ann. Rev. Immunol.</i> 9:159-191
C50	Moore et al., 1980, "Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors," <i>J. Immunol.</i> 125(3):1302-1305
C51	Moreira et al., 1993, "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation," <i>J. Exp. Med.</i> 177:1675-1680
C52	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," <i>Bioorg. Med. Chem. Lett.</i> 9(11):1625-1630
C53	Munshi et al., 1999, <i>Blood</i> 94, Abstract #2577
C54	Ogawa, 1989, "Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation," <i>Environ. Health Perspect.</i> 80:199-207
C55	Peddie et al., 1997, "Oxidative DNA damage in CD34+ myelodysplastic cells in associated with intracellular redox changes and elevated plasma tumor necrosis factor- α concentration," <i>Br. J. Haematol.</i> 99:625-631
C56	Penichet et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," <i>J. Immunol. Methods.</i> 248(1-2):91-101
C57	<i>Physicians' Desk Reference</i> , 2002, 56th ed. pp. 582-592, 1154-1158, 1755-1760
C58	Rajapaksa et al., 1996, "Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells," <i>Blood</i> 88:4275-4287
C59	Raza et al., 2001, "Thalidomide Produces Transfusion Independence in Long-standing Refractory Anemias of Patients with Myelodysplastic Syndromes," <i>Blood</i> 98(4):958-965
C60	Raza et al., 1995, "Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes," <i>Blood</i> 86:268-276
C61	Richardson et al., 2002, "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma," <i>Blood</i> 100:3063-3067
C62	Rose et al., 1995, "The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS)," <i>Br. J. Haematol.</i> 89:831-837
C63	Schrader et al., 1981, "The persisting (P) cell: histamine content, regulation by a T cell-derived factor, origin from a bone marrow precursor, and relationship to mast cells," <i>Proc. Natl. Acad. Sci. USA</i> 78(1):323-327
C64	Singhal et al., 1999, "Antitumor activity of thalidomide in refractory multiple myeloma," <i>N. Engl. J. Med.</i> 341(21):1565-1571
C65	Stanley et al., 1976, "Factors regulating macrophage production and growth: identity of colony-stimulating factor and macrophage growth factor," <i>J. Exp. Med.</i> 143(3):631-647
C66	Tabbara et al., 1991, "Hematopoietic growth factors," <i>Anticancer Res.</i> 11(1):81-90
C67	Tauro et al., 2002, "Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes," <i>Leukemia</i> 16:785-790
C68	Turk et al., 1996, "Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production," <i>PNAS USA</i> 93:7552-7556
C69	Vadas et al., 1983, "Eosinophil activation by colony-stimulating factor in man: metabolic effects and analysis by flow cytometry," <i>Blood</i> 61(6):1232-1241
C70	Vadas et al., 1983, "Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors," <i>J. Immunol.</i> 130(2):795-799
C71	Vasiliauskas et al., 1999, "An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease," <i>Gastroenterology</i> 117(6):1278-1287

C72	Weisbart et al., 1986, "Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors," <i>J. Immunol.</i> 137(11):3584-3587
C73	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed., pp. 172-178, 949-982
C74	Marriott et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," <i>Expert Opin. Biol. Ther.</i> 1(4):675-682
C75	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," <i>J. Med. Chem.</i> 39(17):3238-3240
C76	Hideshima et al. 2000, "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," <i>Blood</i> 96(9):2943-2950
C77	Baker, AF; Bellamy, WT; Glinsmann-Gibson, B; Heaton, R.; Buresh, A.; Grogan, TM; List, AF; "Biological response to Thalidomide in Remitting Patients with Myelodysplastic Syndrome (MDS) Evidence for Induction of Neoplastic Vascular Endothelial Growth Factor (VEGF) Resistance" <i>Blood</i> 2001; 98(11):353a-4a, Abstract #1490.
C78	List, AF; "Pharmacological Differentiation and Anti-Apoptotic Therapy in Myelodysplastic Syndromes;" <i>Forum Trends in Experimental and Clinical Medicine</i> ," 9:35-45,1999.
C79	List, AF; Brasfield, F.; Heaton, R.; Glinsmann-Gibson, B.; Crook, L.; Taetle, R.; Capizzi, R.; "Stimulation of Hematopoiesis by Amifostine in Patients with Myelodysplastic Syndrome. <i>Blood</i> 1997; 90(9): 3364-9.
C80	List, AF; "New Approaches to the Treatment of Myelodysplasia," <i>The Oncologist</i> 2002; 7 Suppl. 1:39-49.
C81	Thomas, D.A., Aguayo, A., Estey, E., Albitar, M., O'Brien, S., Giles, F.J., Beran, M., Cortes, J., Zeldis, J., Keating, M.J., Barlogie, B., Kantarjian, H.M., Thalidomide as anti-angiogenesis therapy (rx) in refractory or relapsed leukemia. Abstract #2269, American Society of Hematology, December 3-7, 1999.
C82	Raza, A., Lisak, L., Andrews, C., Little, L., Muzammil, M., Alvi, S., Mazzoran, L., Zorat, F., Akber, A., Ekbal, M., Razvi, S., Venugopal, P., 2001. "Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS)." <i>Blood</i> 98(4):958-965.
C83	Raza, A., Lisak, L., Andrews, C., Little, L., Zorat, F., Shetty, V., Alvi, S., Mundle, S., Allampallam, K., Durandt, M., Ekbal, M., Muzammil, M., Encouraging improvement in cytopenias of patients with myelodysplastic syndromes (MDS) with thalidomide. Abstract #111, Amer. Soc. of Clinical Oncology, May 20-23, 2000.
C84	Raza, A., Lisak, L., Little, L., Dean, L., Gezer, S., Venugopal, V., Summary and future direction of anti-tumor necrosis factor (TNF) therapies in myelodysplastic syndromes (MDS). Abstract #2700, American Society of Hematology, May 12-17, 2001.
C85	Mundle, S., Zorat, F., Shetty, V., Allampallam, K., Alvi, S., Lisak, L., Little, L., Dean, L., Nascimben, F., Ekbal, M., Durandt, M., Broderick, E., Venugopal, P., Raza, A., Thalidomide in myelodysplasia. Abstract #626, American Society of Hematology, December 1-5, 2000.
C86	Raza, A., Lisak, L., Little, L., Ekbal, M., Durandt, M., Ali, E., Nascimben, F., Tareen, M., Venugopal, P., Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or enbrel in myelodysplastic syndromes (MDS). Abstract #627, American Society of Hematology, December 1-5, 2000.
C87	Estey, E., Albitar, M., Cortes, J., Giles, F., Thomas, D., Koller, C., Beran, M., Kantarjian, H., Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. Abstract #1394, American Society of Hematology, December 1-5, 2000.
C88	Alvi, S., Henderson, B., Shafer, A., Dangerfield, B., Broderick, E., Jafri, N., Tareen, M., Durandt, M., Galili, N., Borok, R.Z., Raza, A., Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. Abstract #1536, American Society of Hematology, December 1-5, 2000.
C89	Alvi, S., Shafer, A., Henderson, B., Dar, S., Zorat, F., Broderick, E., Lisak, L., Durandt, M., Reddy, P., Mundle, S., Galili, N., Borok, R.Z., Raza, A., Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. Abstract #1547, American Society of Hematology, December 1-5, 2000.
C90	Dourado, C. Mc., Seixas-Silva Jr., J.A., Besa, E.C., Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. Abstract #4855, American Society of Hematology, December 1-5, 2000.
C91	Lisak, L.A., Little, L., Dean, L., Ekbal, M., Durandt, M., Hussain, M., Kaistha, V., Raza, A., Delayed responses to thalidomide in patients with myelodysplastic syndromes. Abstract #4861, American Society of Hematology, December 1-5, 2000.
C92	Anders, O., Plath, F., Emmrich, J., Freund, M., Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. Abstract #3820, American Society of Hematology, December 7-11, 2001.
C93	Alvi, S., Shafer, A., Shaikh, M., Anthwal, S., Siddiqi, F., Akhtar, A., Ashraf, H., Meager, R., Mundle, S., Shetty, V., Goldberg, C., Galili, N., Borok, R.Z., Raza, A., MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. Abstract #1482, American Society of Hematology, December 7-11, 2001.
C94	Alvi, S., Shaikh, M., Anthwal, S., Shafer, A., Tamoseviciene, D., Novick, A., Reddy, P., Allampallam, K., Hsu, W.T., Galili, N., Borok, R.Z., Raza, A., Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. Abstract #1483, American Society of Hematology, December 7-11, 2001.
C95	Alvi, S., Anthwal, S., Shaikh, M., Shafer, A., Shetty, V., Mundle, S., Reddy, P., Allampallam, K., Bi, S., Zorat, F., Tamoseviciene, D., Rasila, K., Meagher, R., Westbrook, C., Galili, N., Gezer, S., Venugopal, P., Borok, R.Z., Raza, A., Thalidomide significantly augments proliferation and cytokine secretion to bone marrow cultures established from myelodysplastic syndrome (MDS) patients. Abstract #1484, American Society of Hematology, December 7-11, 2001.
C96	Musto, P., Falcone, A., Bodenizza, C., Sanpaolo, G., Matera, R., Bisceglia, M., Carella, A.M., Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS):

		relationship to serum and marrow levels of angiogenetic growth factors (AGF). Abstract #2606, American Society of Hematology, December 7-11, 2001.
	C97	Fabbri, A., Biscardi, M., Innocenti, F., Balestri, G., Gavazzi, S., Bellesi, G., Grossi, A., Thalidomide in combination with Amifostine in the treatment of MDS: evaluation of clinical and laboratory findings. Abstract #4819, American Society of Hematology, December 7-11, 2001.
	C98	Raza, A., Lisak, L., Dutt, D., Dean, L., Fantroy, L., Ali, E., Gezer, S., Hsu, W-T., Goldberg, C., Loew, J., Venugopal, P., Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). Abstract #4830, American Society of Hematology, December 7-11, 2001.
	C99	Raza, A., Dutt, D., Lisak, L., Dean, L., Fantroy, L., Gezer, S., Ali, E., Goldberg, C., Loew, J., Hsu, W-T., Venugopal, P., Combination of thalidomide and enbrel for the treatment of patients with myelodysplastic syndromes (MDS). Abstract #4831. American Society of Hematology, December 7-11, 2001.
	C100	Shetty, V., Allampallam, K., Hussaini, S., Townsend, W., Dutt, D., Mundle, S., Alvi, S., Reddy, P.L., Ashraf, H., Galili, N., Saberwal, G.S., Anthwal, S., Shaikh, M.W., Heidelberg, A., Lisak, L., Gezer, S., Venugopal, P., Raza, A., Effects of anti-cytokine agents on apoptosis, proliferation, monocyte/macrophage number, microvessel density and cytokines following two successive clinical trials in 57 patients with myelodysplastic syndromes (MDS). Abstract #4837. American Society of Hematology, December 7-11, 2001.
	C101	Barlogie, B., Desikan, R., Munshi, N., Siegel, D., Mehta, J., Singhal, S., Anaissie, E., Single Course D.T. Pace Anti-Angiochemotherapy Effects CR in Plasma Cell Leukemia and Fulminant Multiple Myeloma (MM). Abstract #4180. American Society of Hematology, December 4-9, 1998.
	C102	Hideshima, T., Chauhan, D., Shima, Y., Noopur, R., Davies, F.E., Tai, Y., Treon, S.P., Lin, B.K., Schlossman, R.L., Richardson, P.G., Gupta, D., Muller, G.W., Stirling, D.I., Anderson, K.C., Thalidomide (THAL) and its Analogs Overcome Drug Resistance of Human Multiple Myeloma (MM) Cells to Conventional Therapy. Abstract #1313. American Society of Hematology, December 1-5, 2000.
	C103	Payvandi, F., Wu, L., Gupta, D., Hideshima, T., Haley, M., Muller, G., Chen, R., Anderson, K.C., Stirling, D., Effects of a Thalidomide Analog on Binding Activity of Transcription Factors and Cell Cycle Progression of Multiple Myeloma Cell Lines. Abstract #2487. American Society of Hematology, December 1-5, 2000.
	C104	Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y., Lin, B.K., Podar, K., Chauhan, D., Treon, S.P., Gupta, D., Mitsiades, C., Mitsiades, N., Hayashi, T., Richardson, P.G., Schlossman, R.L., Muller, G.W., Stirling, D. I., Anderson, K.C., Thalidomide (THAL) and Immunomodulatory Derivatives (IMiDS) Augment Natural Killer (NK) Cell Cytotoxicity in Multiple Myeloma (MM). Abstract #3617. American Society of Hematology, December 1-5, 2000.
	C105	Hideshima, T., Chauhan, D., Castro, A., Hayashi, T., Mitsiades, C., Mitsiades, N., Akiyama, M., Richardson, P.G., Schlossman, R.L., Adams, J., Anderson, K.C., NF-KB as a Therapeutic Target in Multiple Myeloma (MM). Abstract #1581. American Society of Hematology, December 7-11, 2001.
	C106	Lentsch, S., Rogers, M., Leblanc, R., Birsner, A., Shah, J., Anderson K., D'Amato R., 3-Amino-Phthalimido-Glutarimide (S-3APG) Inhibits Angiogenesis and Growth in Drug Resistant Multiple Myeloma (MM) <i>in vivo</i> . Abstract #1976, American Society of Hematology, December 7-11, 2001.
	C107	Park, Y., Kim, S.A., Kim, C.J., Chung, J.H., Mechanism of the Effect of Thalidomide on Human Multiple Myeloma Cells. Abstract #2685. American Society of Clinical Oncology, May 12-17, 2001.

EXAMINER	DATE CONSIDERED
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.</small></p>	